Caspofungin versus anidulafungin in patients with invasive candidiasis: a retrospective study with propensity-score-matched analysis
<h3>Background</h3><p dir="ltr">Echinocandins are recommended as an initial treatment for invasive candidiasis. Although safety and efficacy profiles of both anidulafungin and caspofungin are well established, direct head-to-head comparisons have not been reported before....
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , |
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513533555769344 |
|---|---|
| author | Reem Hasan Elajez (22504292) |
| author2 | Dana Bakdach (9538569) Sara Al Balushi (13995363) Ahmed Zaqout (9538566) Rand Alattar (18507101) Tasneem Abdallah (17380486) Waleed Awouda (17128777) Godwin Wilson (21324152) Walid Al-Wali (18466216) Emad Ibrahim (3567056) Hussam Alsoub (14777305) |
| author2_role | author author author author author author author author author author |
| author_facet | Reem Hasan Elajez (22504292) Dana Bakdach (9538569) Sara Al Balushi (13995363) Ahmed Zaqout (9538566) Rand Alattar (18507101) Tasneem Abdallah (17380486) Waleed Awouda (17128777) Godwin Wilson (21324152) Walid Al-Wali (18466216) Emad Ibrahim (3567056) Hussam Alsoub (14777305) |
| author_role | author |
| dc.creator.none.fl_str_mv | Reem Hasan Elajez (22504292) Dana Bakdach (9538569) Sara Al Balushi (13995363) Ahmed Zaqout (9538566) Rand Alattar (18507101) Tasneem Abdallah (17380486) Waleed Awouda (17128777) Godwin Wilson (21324152) Walid Al-Wali (18466216) Emad Ibrahim (3567056) Hussam Alsoub (14777305) |
| dc.date.none.fl_str_mv | 2025-08-02T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1177/20499361251344777 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Caspofungin_versus_anidulafungin_in_patients_with_invasive_candidiasis_a_retrospective_study_with_propensity-score-matched_analysis/30455933 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biological sciences Microbiology Biomedical and clinical sciences Pharmacology and pharmaceutical sciences Health sciences Epidemiology anidulafungin caspofungin invasive candidiasis |
| dc.title.none.fl_str_mv | Caspofungin versus anidulafungin in patients with invasive candidiasis: a retrospective study with propensity-score-matched analysis |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Background</h3><p dir="ltr">Echinocandins are recommended as an initial treatment for invasive candidiasis. Although safety and efficacy profiles of both anidulafungin and caspofungin are well established, direct head-to-head comparisons have not been reported before.</p><h3>Objective</h3><p dir="ltr">Compare efficacy and safety of anidulafungin versus caspofungin among patients with invasive candidiasis.</p><h3>Design</h3><p dir="ltr">Retrospective observational study.</p><h3>Methods</h3><p dir="ltr">Adult patients with invasive candidiasis who were treated with either anidulafungin or caspofungin for ⩾5 days were retrospectively reviewed over a period of 6 years. The primary endpoint was global response, defined as clinical and microbiological success at the end of treatment duration.</p><h3>Results</h3><p dir="ltr">A total of 223 patients who received either anidulafungin ( <i>n</i> = 176) or caspofungin ( <i>n</i> = 47) were initially included. Propensity score matching (based on age, malignancy, level of care, presence of candidemia, and other factors) was performed to improve comparability of the two groups. As a result, 32 patients in the caspofungin arm and 79 patients in the anidulafungin arm were included in the final analysis. Around three-quarters of the cohort had candidemia, and the most common isolated <i>Candida</i> species were <i>C. albicans </i>and <i>C. glabrata</i> . Response rates were comparable between both groups, with the primary outcome of global response showing no significant difference (56.3% for the caspofungin group vs 63.3% for anidulafungin,<i> p</i> = 0.490). Similarly, no differences between the two groups were observed in terms of 90-day all-cause mortality ( p = 0.672) or any other secondary endpoints.</p><h3>Conclusion</h3><p dir="ltr">Our data suggest that anidulafungin and caspofungin have comparable global response among patients with invasive candidiasis. Additionally, both studied echinocandins showed no significant difference in 90-day all-cause mortality. However, due to the limited sample size, larger studies are needed to confirm these results.</p><h2>Other Information</h2><p dir="ltr">Published in: Therapeutic Advances in Infectious Disease<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1177/20499361251344777" target="_blank">https://dx.doi.org/10.1177/20499361251344777</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_6add24b8f7fd888bd28f6c8cb69a1065 |
| identifier_str_mv | 10.1177/20499361251344777 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/30455933 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Caspofungin versus anidulafungin in patients with invasive candidiasis: a retrospective study with propensity-score-matched analysisReem Hasan Elajez (22504292)Dana Bakdach (9538569)Sara Al Balushi (13995363)Ahmed Zaqout (9538566)Rand Alattar (18507101)Tasneem Abdallah (17380486)Waleed Awouda (17128777)Godwin Wilson (21324152)Walid Al-Wali (18466216)Emad Ibrahim (3567056)Hussam Alsoub (14777305)Biological sciencesMicrobiologyBiomedical and clinical sciencesPharmacology and pharmaceutical sciencesHealth sciencesEpidemiologyanidulafungincaspofungininvasive candidiasis<h3>Background</h3><p dir="ltr">Echinocandins are recommended as an initial treatment for invasive candidiasis. Although safety and efficacy profiles of both anidulafungin and caspofungin are well established, direct head-to-head comparisons have not been reported before.</p><h3>Objective</h3><p dir="ltr">Compare efficacy and safety of anidulafungin versus caspofungin among patients with invasive candidiasis.</p><h3>Design</h3><p dir="ltr">Retrospective observational study.</p><h3>Methods</h3><p dir="ltr">Adult patients with invasive candidiasis who were treated with either anidulafungin or caspofungin for ⩾5 days were retrospectively reviewed over a period of 6 years. The primary endpoint was global response, defined as clinical and microbiological success at the end of treatment duration.</p><h3>Results</h3><p dir="ltr">A total of 223 patients who received either anidulafungin ( <i>n</i> = 176) or caspofungin ( <i>n</i> = 47) were initially included. Propensity score matching (based on age, malignancy, level of care, presence of candidemia, and other factors) was performed to improve comparability of the two groups. As a result, 32 patients in the caspofungin arm and 79 patients in the anidulafungin arm were included in the final analysis. Around three-quarters of the cohort had candidemia, and the most common isolated <i>Candida</i> species were <i>C. albicans </i>and <i>C. glabrata</i> . Response rates were comparable between both groups, with the primary outcome of global response showing no significant difference (56.3% for the caspofungin group vs 63.3% for anidulafungin,<i> p</i> = 0.490). Similarly, no differences between the two groups were observed in terms of 90-day all-cause mortality ( p = 0.672) or any other secondary endpoints.</p><h3>Conclusion</h3><p dir="ltr">Our data suggest that anidulafungin and caspofungin have comparable global response among patients with invasive candidiasis. Additionally, both studied echinocandins showed no significant difference in 90-day all-cause mortality. However, due to the limited sample size, larger studies are needed to confirm these results.</p><h2>Other Information</h2><p dir="ltr">Published in: Therapeutic Advances in Infectious Disease<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1177/20499361251344777" target="_blank">https://dx.doi.org/10.1177/20499361251344777</a></p>2025-08-02T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1177/20499361251344777https://figshare.com/articles/journal_contribution/Caspofungin_versus_anidulafungin_in_patients_with_invasive_candidiasis_a_retrospective_study_with_propensity-score-matched_analysis/30455933CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/304559332025-08-02T03:00:00Z |
| spellingShingle | Caspofungin versus anidulafungin in patients with invasive candidiasis: a retrospective study with propensity-score-matched analysis Reem Hasan Elajez (22504292) Biological sciences Microbiology Biomedical and clinical sciences Pharmacology and pharmaceutical sciences Health sciences Epidemiology anidulafungin caspofungin invasive candidiasis |
| status_str | publishedVersion |
| title | Caspofungin versus anidulafungin in patients with invasive candidiasis: a retrospective study with propensity-score-matched analysis |
| title_full | Caspofungin versus anidulafungin in patients with invasive candidiasis: a retrospective study with propensity-score-matched analysis |
| title_fullStr | Caspofungin versus anidulafungin in patients with invasive candidiasis: a retrospective study with propensity-score-matched analysis |
| title_full_unstemmed | Caspofungin versus anidulafungin in patients with invasive candidiasis: a retrospective study with propensity-score-matched analysis |
| title_short | Caspofungin versus anidulafungin in patients with invasive candidiasis: a retrospective study with propensity-score-matched analysis |
| title_sort | Caspofungin versus anidulafungin in patients with invasive candidiasis: a retrospective study with propensity-score-matched analysis |
| topic | Biological sciences Microbiology Biomedical and clinical sciences Pharmacology and pharmaceutical sciences Health sciences Epidemiology anidulafungin caspofungin invasive candidiasis |